TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01492153
Drug: human soluble insulin
Normalized name: Recombinant human soluble insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
Study: NCT00311155
Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.
Study: NCT03017235
Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as two 160 mL ready-to-drink bottles, per subject, without further reconstitution, before administration.
Study: NCT02534571
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epinephrine injection endoscopically \<20 mls
Study: NCT01646177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03536507
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT01005069
Drug: DLBS-32
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLBS-32 50 mg once daily and lifestyle modification
Study: NCT01005069
Drug: DLBS-32
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLBS-32 100 mg once daily and lifestyle modification
Study: NCT01005069
Drug: DLBS-32
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLBS-32 200 mg once daily and lifestyle modification
Study: NCT01005069
Drug: DLBS-32
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLBS-32 300 mg once daily and lifestyle modification
Study: NCT01005069
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules once daily and lifestyle modification
Study: NCT00519246
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol tartrate 1 mg i.v.
Study: NCT00519246
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol Tartrate 2 mg i.v.
Study: NCT02351440
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00004928
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00440180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT00259818
Drug: EM-1421
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01529320
Drug: Adventan® (methylprednisolone aceponate 0,1%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses: 1/4 FTU (Finger Tip Unit) during 5 days (Day 7-Day 11). Procedure: Patch Test (Nickel sulphate 5%) during 2 days (Day 0- Day 2.
Study: NCT02200653
Drug: High dose of MICARDIS®, once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02200653
Drug: Low dose of MICARDIS®, once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02200653
Drug: Low dose of COZAAR® / LORZAAR®, once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02200653
Drug: High dose of COZAAR® / LORZAAR®, once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02200653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00368927
Drug: sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT04521751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo capsules
Study: NCT00360295
Drug: Azithromycin SR
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04398823
Drug: Sclersing liqiud of Lauromacrogol
Normalized name: lauromacrogols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in LS will receive enteroscopy with the sclerosing liquid of lauromacrogol.
Study: NCT00009659
Drug: CDB 2914
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02229851
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.
Study: NCT03235752
Drug: TJ301 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ301 300mg IV infusion
Study: NCT03235752
Drug: TJ301 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ301 600mg IV infusion
Study: NCT03235752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV infusion
Study: NCT00074477
Drug: R092670
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00613743
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo solution Quinine diHCl 0.3% at 50 mg/15 ml mouthwash 6 time/day
Study: NCT03211117
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00249964
Drug: Combination Treatment - Cohort 1
Normalized name: Combinations of drugs for treatment of tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 75 mg/m2 per day from day 2 to day 6.
Study: NCT00249964
Drug: Combination Treatment - Cohort 2
Normalized name: Combinations of drugs for treatment of tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 100 mg/m2 per day from day 2 to day 6.
Study: NCT00249964
Drug: Combination Treatment - Cohort 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 125 mg/m2 per day from day 2 to day 6.
Study: NCT00249964
Drug: Combination Treatment - Cohort 4
Normalized name: Combinations of drugs for treatment of tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 150 mg/m2 per day from day 2 to day 6.
Study: NCT03617900
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose monohydrate 400 mg/capsules
Study: NCT00831662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One to two drops in each eye QID for 6 weeks
Study: NCT01854294
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
Study: NCT03360448
Drug: Ad5.hAC6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
Study: NCT03360448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
Study: NCT01675453
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02169895
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02169895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02169895
Drug: Prolopa®
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa/benserazide 100/25 mg
Study: NCT02342314
Drug: Placebo (Part A and Part B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via SC injection
Study: NCT03312413
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.5 mL·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
Study: NCT01260818
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ml saline is kept in wound for 2 hours before drainage is opened postoperatively
Study: NCT00443170
Drug: omeprazole, caffeine, flurbiprofen, rosiglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02628028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00447564
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 implants
Study: NCT02145468
Drug: Placebo twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo as film-coated, round, plain faced tablets.
Study: NCT02145468
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
Study: NCT00673621
Drug: Technosphere Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
Study: NCT00673621
Drug: Methacholine chloride
Normalized name: Methacholine Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
Study: NCT01640639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, pill, once p.d., 6 weeks
Study: NCT02498912
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00316017
Drug: 7.5% hypertonic saline (HS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 cc dose given as a one-time IV bolus in the pre-hospital setting.
Study: NCT00316017
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 cc dose given as a one-time IV bolus in the pre-hospital setting.
Study: NCT04176133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) single dose administration, no active ingredient. A matching placebo is provided as a sterile, clear, colorless to slightly yellow liquid for IM injection in prefilled vials that are identical in appearance to the vials containing active drug.
Study: NCT04176133
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
Study: NCT01468181
Drug: LY2189265
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01468181
Drug: Sulfonylureas (SU)
Normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU is a pre-study prescribed dose and is not being provided as part of the trial.
Study: NCT01468181
Drug: alpha-glucosidase inhibitor (a-GI)
Normalized name: alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: a-GI is a pre-study prescribed dose and is not being provided as part of the trial.
Study: NCT01468181
Drug: Glinides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glinides is a pre-study prescribed dose and is not being provided as part of the trial.
Study: NCT02419547
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
Study: NCT01645332
Drug: Placebo of DLBS3233
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of DLBS3233 once daily for 12 weeks
Study: NCT01645332
Drug: DLBS3233
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DLBS3233 once daily for 12 weeks
Study: NCT00239018
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00349362
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustanon- 200mg intramuscular testosterone
Study: NCT00349362
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline intramuscular injection every two weeks
Study: NCT00763997
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
Study: NCT00005945
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00763997
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
Study: NCT02957032
Drug: F16IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients first receive an initial run-in dose of 30 Mio IU of F16IL2 on day 1 and escalating doses of F16IL2 on day 1, 8, 15 and 22.~Treatment will be repeated every 28 days for up to three cycles.
Study: NCT00005945
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 25 g/m² IV Days 0, 7, 14, given over a period of 15 minutes to 2 hours
Study: NCT00763997
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day
Study: NCT02108964
Drug: EGF816
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF816 will be dosed once daily. On the first day of each treatment cycle, the patient receives an adequate drug supply for self-administration at home. The investigator will instruct the patient to take EGF816 exactly as prescribed.
Study: NCT00005945
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00763997
Drug: Parecoxib/Valdecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
Study: NCT00005945
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO and IT
Study: NCT00896597
Drug: NRL972
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg NRL972 in 5 mL solution for injection administered as a 15-second intravenous injection on each of four occasions.
Study: NCT00777764
Drug: Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: In a saline solution, full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:100,000 and 1:10,000 were followed by 20 minutes of observation.~For the skin prick test, participants were tested initially by positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were made in saline.
Study: NCT00581893
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin will be dosed to a target dose of 5 mg/kg qhs for one month
Study: NCT00581893
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03663673
Drug: EpiCeram
Normalized name: EPICERAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
Study: NCT03663673
Drug: Aveeno Daily Moisturising Sheer Hydration Lotion®
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
Study: NCT00003397
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02706405
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04496245
Drug: Broncho-Vaxom®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broncho-Vaxom adult capsules® (OM85)
Study: NCT04394377
Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine full anticoagulation strategy
Study: NCT05190783
Drug: TheraCal
Normalized name: TheraCal D2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: light cured resin modified calcium silicate filled liner designed for use in direct and indirect pulp capping
Study: NCT02304705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule three times daily by mouth for 90 days
Study: NCT01896427
Drug: 21-benzyloxy-9alpha-fluoro-16alpha-methylpregna-1,4-dien-11beta,17alpha-diol-3,20-dione
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of dexamethasone (8mg) will injected
Study: NCT04020185
Drug: IMSA101
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
Study: NCT04020185
Drug: Immuno-oncology (IO) therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered according to product label
Study: NCT02260947
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 600 mg
Study: NCT02260947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT01704404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02335593
Drug: Epoetin alfa 2000-4000 IU solution for injection
Normalized name: epoetin alfa 4000 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alfa 2000-4000 IU solution for injection
Study: NCT02335593
Drug: Iron Hydroxide Saccharate Complex Solution for injection
Normalized name: saccharated iron oxide
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron Hydroxide Saccharate Complex Solution for injection
Study: NCT02476006
Drug: placebo (for injection training only)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT02476006
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02476006
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT00567567
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00567567
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04521556
Drug: Continuous intravenous analgesia
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
Study: NCT03286218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04407689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) placebo (normal saline) at the same frequency
Study: NCT01071655
Drug: BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1~BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1~BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly~BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly
Study: NCT03656484
Drug: Tetracycline-Metronidazole (TM) group
Normalized name: bismuth biskalcitrate / metronidazole / tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
Study: NCT03656484
Drug: TM-Melatonin-Hyaluronic acid (TM-MHa) group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
Study: NCT01348139
Drug: AZD3199
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled via single inhaler device (SID)
Study: NCT01348139
Drug: AZD3199
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled via Turbuhaler inhaler
Study: NCT04396223
Drug: Methotrexate 1 GM Injection
Normalized name: methotrexate 1 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: methotrexate administration at 1mg/kg/day during 4 months ½ (median)
Study: NCT02545829
Drug: HIP1302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir 292mg
Study: NCT02545829
Drug: HGP1406
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir 300mg